Hallo Biotechs: Kursziel 10 Euro

Hallo Biotechs,

schaut Euch mal den Wert Cadus an: Nicht umsonst hab ich Euch diesem empfohlen:

http://www.ragingbull.com/mboard/boards.cgi?board=KDUS

Viel Spaß dabei...

 

sagen????

Dabei sind die doch ganz spannend.. Patente, Lizenzvergaben der neuen Produkte ....  

KDUS

Decoding the human genome will yield a bounty of biotech miracles that will transform our lives in the future,
Biotech pioneers like KDUS will seek out the genetic bad actors behind our worst scourges, from arthritis to Alzheimers, which in turn will lead to hundreds of new therapies. They'll find genes underlying idiosyncracies like aptitude for math or low pain threshold. They'll pinpoint scant 1% or so of our DNA that separate us from chimps. THey'll trek into deep time to investigate how anient networks of genes taught ourselves to assemble the fabulous jack in the box of new born's brain and the monstorous one of a tumor cell. We'll start winning the war on cancer and solve the medical problems that have plagued humans.

If this has a price tag, then the shareholders of KDUS will be richly rewarded. KDUS holds a few pieces to this puzzle. We will see the surgence of this stock in the near future. We will see the future of medicine in our lifetime. KDUS will either be acquired by a major player in the biotech field or the Company will be a dominant force with its various patents in the area of genome studies.

 

sich den 10 Euro!!!!!!



http://companies.altavista.com/factsheet?id=902467091

 

Hello. I am a recent KDUS investor and this is my first post on this board. I decided to call Cadus today because I've been having fits trying to find reliable info. on the company through the usual DD. Dr. Woler (Pres./CEO)himself answered the phone and very patiently answered my questions and addressed the future of Cadus. The following is a brief recounting of our conversation which I believe to be accurate, however, if you wish to "hear it from the horse's mouth" you can try calling Dr. Woler at 212-702-4366.

While two patent assets were sold to OSI Pharmaceuticals in August 1999, six patents remain, and these patents comprise the entire G protein-coupled receptor (GPCR)yeast technology database. It is this technology which has been leased to OSI, and which Dr. Woler believes will be leased to other companies within the upcoming weeks and months. (I was glad to hear that, didn't want the deal with their former associates to be the sum of Cadus' prospects).

Carl Icahn still owns 27% of KDUS stock and has been working with Dr. Woler to explore options for the future of the company. Dr. Woler mentioned the possibility of merger/acquisition activities, as Cadus is seen as an attractive shell corporation with viable proprietary technology, good cash on hand (approx. $5.5 million in the bank), and virtually no overhead expenses. Also, Cadus still owns 30% of Axiom, a small company engaged in gene mapping. Axiom is currently privately held, but Dr. Woler understands that an IPO would be most beneficial to shareholders of Cadus, and as a boardmember of Axiom, he may be able to push Axiom in this direction.

As for KDUS's recent run-up, Dr. Woler points to the excitement surrounding the OSI Pharmaceuticals deal and the possibilities of future non-exclusive liscencing deals with other companies, as well as general market conditions. He said he's been getting lots of phone calls lately, and it seems the market is starting to take notice of Cadus. Above all, Dr. Woler stressed that Cadus is actively seeking ways to increase shareholder value and will continue to do so indefinitely.

I hope this helps shed some light on the company, and like I said, you can call yourself and ask your own questions. Please get back to me with any additional information you uncover, you can never know too much. Good luck.  

(1 of 1)



--------------------------------------------------
United States Patent  6,037,340
Castelhano, et. al. Mar. 14, 2000

--------------------------------------------------
Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
Abstract

Methods for preparing thiophene and pyrrole-based heterocyclic compounds are disclosed. Also disclosed are libraries of thiophene and pyrrole-based heterocyclic compounds, methods for preparing the libraries of thiophene and pyrrole-based heterocyclic compounds, and methods for using the thiophene and pyrrole-based heterocyclic compounds and compound libraries of the invention. The compounds of the invention have biological activity including anti-cancer activity.



--------------------------------------------------
Inventors:  Castelhano; Arlindo L. (New City, NY); McKibben; Bryan (White Plains, NY).  
Assignee:  Cadus Pharmaceutical Corporation (Tarrytown, NY).  
Appl. No.:  864,240
Filed:  May 28, 1997
Intl. Cl. :  A61K 31/38, A61K 31/40, A61K 31/435, C07D 205/02
Current U.S. Cl.:  514/183; 514/342; 514/422; 514/443; 514/447; 540/480; 540/596; 546/280.4; 548/527; 548/950; 548/962; 549/50; 549/68; 549/69
Field of Search:  514/443, 447; 549/68, 69, 50

--------------------------------------------------

References Cited | [Referenced By]

--------------------------------------------------

U.S. Patent Documents
1,642,462 Sept., 1927 Reach 473/290
3,732,212 May, 1973 Carabateas 260/239.3
3,904,603 Sept., 1975 Kim 260/239
3,925,361 Dec., 1975 Kim 260/239
3,947,408 Mar., 1976 Wright, Jr. 260/239.3
3,984,103 Oct., 1976 Nix 473/291
4,147,349 Apr., 1979 Jeghers 473/291
4,256,878 Mar., 1981 Klaus et al. 542/412
4,346,161 Aug., 1982 Krutak et al. 430/223
5,228,688 Jul., 1993 Davis 473/290
5,565,324 Oct., 1996 Still et al. 435/6


Foreign Patent Documents
0006154 Jan., 1980 EP  
0207345 Jan., 1987 EP  
0364598 Apr., 1990 EP  
0399814 Nov., 1990 EP  
2513337 Oct., 1976 DE  
2724445 Dec., 1977 DE  
4029771 Mar., 1992 DE  
4119767 Dec., 1992 DE  
1394366 May, 1975 GB  
WO 93/08197 Apr., 1993 WO  
WO 9408051 Apr., 1994 WO  

Other References
Combinatorial Synthesis of Small Organic Molecules, F. Balkenhol et al., Angew. Chem. Int. Ed. Engl. (1996), 35, 2288-2337.

Certified English Translation of K. Gewald et al. Chem. Ber., pp. 1-10, 1996, vol. 99, 94.

Carabateas, P.M. et al. "Analgesic Antagonists. I. 4-Substituted 1-Acyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepines" J. Med. Chem. 9:6-10 (1966).

DeGrado, W.F. et al. "Polymer-Bound Oxime Esters as Supports for Solid-Phase Peptide Synthesis. Preparation of Protected Peptide Fragments" J. Org. Chem. 45:1295-1300 (1980).

DeWitt, S.H. et al "Diversomers: An Approach to Nonpeptide, Nonoligomeric Chemical Diversity" Proc. Natl. Acad. Sci. USA 90:6909-6913 (1993).

Errede, L.A. et al. "Acylanthranils.3. The Influence of Ring Substituents on Reactivity and Selectivity in the Reaction of Acylanthranils with Amines" J. Org. Chem. 42(1):12-18 (1977).

Foster, C.H. et al. "Novel One-Pot Synthesis of 4-Aminoquinazolines" J. Org. Chem. 41(15) :2646-2647 (1976).

Gewald, K. et al. "2-Amino-thiopene aus methylenaktiven Nitrilen, Carbonylverbindungen und Schwefel" Chem. Ber. 99:94-100 (1966).

Gordon, E.M. et al. "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions" Journal of Medical Chemistry 37(10):1385-1401 (1994).

Houghten, R.A. et al. "Generation and Use of Synthetic Peptide Cominatorial Libraries for Basis Research and Drug Discovery" Naturem 354:84-86 (1991).

Kim, D.H. "Improved Synthesis of 1,4-Benzodiazepine-2,5-diones" J. Heterocyclic Chem.12:1323-1324 (1975).

Mayer, J.P. et al. "Solid Phase Synthesis of 1,4-Benzodiazepine-2,5-diones" Tetrahedron Letters 37(45):8081-8084 (1996).

Mitscher, L.A. et al. "Quinolone Antimicrobial Agents. 1. Versatile New Synthesis of 1-Alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acids" Journal of Medical Chemistry 21(5):485-489 (1978).

Molina, P. et al. "Heterocyclic Synthesis via a Tandem Aza-wittig Reaction/Heterocumulene-mediated Annulation reaction. New Methodology for the Preparation of Quinazoline Derivatives" Tetrahedron Letters 29(31):3849-3852 (1988).

Muller, C.E. et al. "Chiral Pyrrolo[2,3-d]pyrimidine and Pyrimido[4,5-b]indole Derivatives: Structure-Activity Relationships of Potent, Highly Stereoselective A(1) -Adenosine Receptor Antagonists" J. Med. Chem. 39:2482-2491 (1996).

Roth, H.J. et al. "Synthese von 2-Amino-3-cyano-pyrrolen" Arch. Pharmaz. 308(75):179-185 (1975).

Sampson, N.S. et al. "Attempted de Novo Design, Synthesis, and Evaluation of a Ligand for the Allosteric Site of Phosphofructokinase" J. Org. Chem. 56:7179-7183 (1991).

Takashi, M. et al. Nippon Kaguku Kaishi 8:1259 (1972).


Primary Examiner: Richter; Johann
Assistant Examiner: Solola; Taofiq A.
Attorney, Agent or Firm: Lahive & Cockfield, LLPDeConti, Jr. Esq.; Giulio A., Lauro, Esq.; Peter C.

64 Claims, No Drawings

--------------------------------------------------